The carcinogenic impact of miR-193a-3p has been attributed to its repression of c-Kit[18] and the PTEN/PI3K signaling pathway in acute myeloid leukemia[19], of KRAS and PLAU in colon cancer[20], of PLAU[21] and EGFR-driven cell-cycle network proteins[22] in breast cancer, of ARHGAP19, CCND1, ERBB4, KRAS and Mcl-1 in epithelial ovarian cancer[23], of PLAU in hepatocellular carcinoma (HCC)[24], and of Mcl-1 in NSCLC[25]. The gene discussed is PLAU; the disease is hepatocellular carcinoma.